Shamim Ruff Biography and Net Worth

Shamim Ruff has served as a member of the Board since April 2021. Ms. Ruff brings over 30 years of
experience in the biopharmaceutical industry, serving in various regulatory roles. Ms. Ruff has served as Chief Regulatory Affairs Officer and Senior Vice President, Head of Quality Assurance, at Stoke Therapeutics, Inc. since December 2018. From January 2013 to May 2018, Ms. Ruff served in various roles at Sarepta Therapeutics, Inc., including as Chief Regulatory Officer and Senior Vice President, Quality, from December 2015 to May 2018. Prior to her time at Sarepta Therapeutics, Inc., Ms. Ruff served in increasingly senior regulatory roles at Sanofi, Amgen Inc., Abbott Laboratories and AstraZeneca PLC. Ms. Ruff holds a bachelor’s degree in Chemistry and Biology from the University of Leicester, UK, and a master’s degree in Analytical Chemistry from the University of Loughborough, UK. Additionally, she is a Chartered Chemist and Member of the Royal Society of Chemistry. Our Board believes Ms. Ruff is qualified to serve on our Board due to her extensive regulatory experience at biopharmaceutical companies.

What is Shamim Ruff's net worth?: The estimated net worth of Shamim Ruff is at least $1.27 million as of July 28th, 2023. Ms. Ruff owns 7,359 shares of Reata Pharmaceuticals stock worth more than $1,268,397 as of April 28th. This net worth estimate does not reflect any other investments that Ms. Ruff may own. Learn More about Shamim Ruff's net worth.
How do I contact Shamim Ruff?: The corporate mailing address for Ms. Ruff and other Reata Pharmaceuticals executives is 5320 LEGACY DRIVE, PLANO TX, 75024. Reata Pharmaceuticals can also be reached via phone at (972) 865-2219 and via email at [email protected]. Learn More on Shamim Ruff's contact information.
Has Shamim Ruff been buying or selling shares of Reata Pharmaceuticals?: Shamim Ruff has not been actively trading shares of Reata Pharmaceuticals within the last three months. Most recently, Shamim Ruff sold 8,235 shares of the business's stock in a transaction on Friday, July 28th. The shares were sold at an average price of $164.53, for a transaction totalling $1,354,904.55. Following the completion of the sale, the director now directly owns 7,359 shares of the company's stock, valued at $1,210,776.27. Learn More on Shamim Ruff's trading history.
Who are Reata Pharmaceuticals' active insiders?: Reata Pharmaceuticals' insider roster includes Bhaskar Anand (CAO), Dawn Bir (Chief Commercial Officer), Elaine Castellanos (CAO), Samina Khan (SVP), Andrea Loewen (SVP), Colin Meyer (Insider), Shamim Ruff (Director), Manmeet Soni (CFO), and Michael Wortley (Insider). Learn More on Reata Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Reata Pharmaceuticals?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 236,092 shares worth more than $31,588,041.37. The most recent insider tranaction occured on September, 14th when SVP Andrea Loewen sold 3,175 shares worth more than $546,195.25. Insiders at Reata Pharmaceuticals own 26.8% of the company. Learn More about insider trades at Reata Pharmaceuticals.
Information on this page was last updated on 9/14/2023.

Shamim Ruff Insider Trading History at Reata Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/28/2023	Sell	8,235	$164.53	$1,354,904.55	7,359
3/10/2023	Sell	5,740	$83.73	$480,610.20	5,223

Shamim Ruff Buying and Selling Activity at Reata Pharmaceuticals

Reata Pharmaceuticals Company Overview

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Today's Range

Now: $172.36

$172.32

$172.46

50 Day Range

MA: $171.30

$168.70

$172.36

2 Week Range

Now: $172.36

$21.83

$172.46

Volume

1,988,500 shs

Average Volume

1,091,032 shs

Market Capitalization

$6.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy